Comparison · NCT01208922-acbb2f8a
Group A vs Group B: Number of Patients With Clinical Cure
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: Number of Patients With Clinical Cure. Trial comparisons, record NCT01208922-acbb2f8a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01208922-acbb2f8a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.85 | 0.813 | 0.881 | wilson | |
| Risk in group 2 | 0.848 | 0.81 | 0.88 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00181 | -0.0469 | 0.0506 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.946 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.694 | 1.48 | log | |
| Number needed to treat, for one more participant with the outcome on Group A than on Group B | 553 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | Rifamycin SV-MMX® 200 mg tablets~Rifamycin SV-MMX®: 2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d. | 357 | 420 | OG000 |
| Group 2 | Group B | Ciprofloxacin 500 mg capsules~Ciprofloxacin: 1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d. | 352 | 415 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Clinical Cure
- Description
Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection.
- Time frame
- 5 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
- NCT number
- NCT01208922
- Phases
- PHASE3
- Conditions
- Traveler's Diarrhea
- Interventions
- Rifamycin SV-MMX®, Ciprofloxacin
- Lead sponsor
- Dr. Falk Pharma GmbH
- Results first posted
- 2019-02-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01208922?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01208922-acbb2f8a